Personalis

Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study.

Under the non-exclusive deal, Natera will use matched tumor and normal exome sequencing data from Personalis to validate the design of its Signatera ctDNA assays.

Get the latest news from Invitae, Exact Sceicnes, Danaher, SkylineDx, Personalis, and Seegene for the week of 6/28/19.

Get the latest news from Ivivoscribe, Todos Medical, Personalis, and Thermo Fisher Scientific for the week of 5/24/19.

Enzo Biochem and its subsidiary Enzo Life Sciences announced this week that the Patent Trial and Appeal Board has denied a petition filed by Hologic for inter partes review, a procedure for challenging the validity of patent claims, against US Patent 6,221,581.

The firm has received approval for two unspecified clinical tests, with a permit under the molecular genetic testing category.